Early clinical investigation of Viozan (sibenadet HCl), a novel D2 dopamine receptor, β2-adrenoceptor agonist for the treatment of chronic obstructive pulmonary disease symptoms: Developing new therapies for chronic obstructive pulmonary disease: lessons learned from the novel D2/β2 agonist, ViozanTM

Early clinical investigation of Viozan (sibenadet HCl), a novel D2 dopamine receptor, β2-adrenoceptor agonist for the treatment of chronic obstructive pulmonary disease symptoms: Developing new therapies for chronic obstructive pulmonary disease: lessons learned from the novel D2/β2 agonist, ViozanTM

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Respiratory medicine 2003, Vol.97, p.S9-S21
Hauptverfasser: IND, P. W, LAITINEN, L, LAURSEN, L, WENZEL, S, WOUTERS, E, DEAMER, L, NYSTROM, P
Format: Artikel
Sprache:eng
Schlagworte:
Biological and medical sciences
Chronic obstructive pulmonary disease, asthma
Medical sciences
Pneumology
Respiratory system : syndromes and miscellaneous diseases
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page S21
container_issue
container_start_page S9
container_title Respiratory medicine
container_volume 97
creator IND, P. W
LAITINEN, L
LAURSEN, L
WENZEL, S
WOUTERS, E
DEAMER, L
NYSTROM, P
description
format Article
fullrecord <record><control><sourceid>pascalfrancis</sourceid><recordid>TN_cdi_pascalfrancis_primary_16111660</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16111660</sourcerecordid><originalsourceid>FETCH-pascalfrancis_primary_161116603</originalsourceid><addsrcrecordid>eNqNT9tKw0AQXUTBePmHeREUGthcGuhzrfQDxNcy3Uzakc1s2NkG4mf1Q_wmU_QDfDqHc5nhXJmsWFZlXtmmvjaZXS3rvCmK4tbcqX5aa1d1bTNz3mD0EzjPwg49sIykiQ-YOAiEDj44fKHAs_KeBFtKsF37lwUgSBjJw2sJbRiwZyGI5GhIIS7g-1zm2EaS8KsAHoKwJuhmno4EKRKmniRdfrhjnF0HYa8pnlzikWA4-T4IxglaVkIl0KmfT_X6YG469EqPf3hvnt427-ttPqDOE7qI4lh3Q-R-ru-Ky-qmsdV_cz9-02d4</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Early clinical investigation of Viozan (sibenadet HCl), a novel D2 dopamine receptor, β2-adrenoceptor agonist for the treatment of chronic obstructive pulmonary disease symptoms: Developing new therapies for chronic obstructive pulmonary disease: lessons learned from the novel D2/β2 agonist, ViozanTM</title><source>Elsevier ScienceDirect Journals Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>IND, P. W ; LAITINEN, L ; LAURSEN, L ; WENZEL, S ; WOUTERS, E ; DEAMER, L ; NYSTROM, P</creator><creatorcontrib>IND, P. W ; LAITINEN, L ; LAURSEN, L ; WENZEL, S ; WOUTERS, E ; DEAMER, L ; NYSTROM, P</creatorcontrib><identifier>ISSN: 0954-6111</identifier><identifier>EISSN: 1532-3064</identifier><language>eng</language><publisher>Oxford: Elsevier</publisher><subject>Biological and medical sciences ; Chronic obstructive pulmonary disease, asthma ; Medical sciences ; Pneumology ; Respiratory system : syndromes and miscellaneous diseases</subject><ispartof>Respiratory medicine, 2003, Vol.97, p.S9-S21</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4022</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=16111660$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>IND, P. W</creatorcontrib><creatorcontrib>LAITINEN, L</creatorcontrib><creatorcontrib>LAURSEN, L</creatorcontrib><creatorcontrib>WENZEL, S</creatorcontrib><creatorcontrib>WOUTERS, E</creatorcontrib><creatorcontrib>DEAMER, L</creatorcontrib><creatorcontrib>NYSTROM, P</creatorcontrib><title>Early clinical investigation of Viozan (sibenadet HCl), a novel D2 dopamine receptor, β2-adrenoceptor agonist for the treatment of chronic obstructive pulmonary disease symptoms: Developing new therapies for chronic obstructive pulmonary disease: lessons learned from the novel D2/β2 agonist, ViozanTM</title><title>Respiratory medicine</title><subject>Biological and medical sciences</subject><subject>Chronic obstructive pulmonary disease, asthma</subject><subject>Medical sciences</subject><subject>Pneumology</subject><subject>Respiratory system : syndromes and miscellaneous diseases</subject><issn>0954-6111</issn><issn>1532-3064</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNqNT9tKw0AQXUTBePmHeREUGthcGuhzrfQDxNcy3Uzakc1s2NkG4mf1Q_wmU_QDfDqHc5nhXJmsWFZlXtmmvjaZXS3rvCmK4tbcqX5aa1d1bTNz3mD0EzjPwg49sIykiQ-YOAiEDj44fKHAs_KeBFtKsF37lwUgSBjJw2sJbRiwZyGI5GhIIS7g-1zm2EaS8KsAHoKwJuhmno4EKRKmniRdfrhjnF0HYa8pnlzikWA4-T4IxglaVkIl0KmfT_X6YG469EqPf3hvnt427-ttPqDOE7qI4lh3Q-R-ru-Ky-qmsdV_cz9-02d4</recordid><startdate>2003</startdate><enddate>2003</enddate><creator>IND, P. W</creator><creator>LAITINEN, L</creator><creator>LAURSEN, L</creator><creator>WENZEL, S</creator><creator>WOUTERS, E</creator><creator>DEAMER, L</creator><creator>NYSTROM, P</creator><general>Elsevier</general><scope>IQODW</scope></search><sort><creationdate>2003</creationdate><title>Early clinical investigation of Viozan (sibenadet HCl), a novel D2 dopamine receptor, β2-adrenoceptor agonist for the treatment of chronic obstructive pulmonary disease symptoms</title><author>IND, P. W ; LAITINEN, L ; LAURSEN, L ; WENZEL, S ; WOUTERS, E ; DEAMER, L ; NYSTROM, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pascalfrancis_primary_161116603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Biological and medical sciences</topic><topic>Chronic obstructive pulmonary disease, asthma</topic><topic>Medical sciences</topic><topic>Pneumology</topic><topic>Respiratory system : syndromes and miscellaneous diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>IND, P. W</creatorcontrib><creatorcontrib>LAITINEN, L</creatorcontrib><creatorcontrib>LAURSEN, L</creatorcontrib><creatorcontrib>WENZEL, S</creatorcontrib><creatorcontrib>WOUTERS, E</creatorcontrib><creatorcontrib>DEAMER, L</creatorcontrib><creatorcontrib>NYSTROM, P</creatorcontrib><collection>Pascal-Francis</collection><jtitle>Respiratory medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>IND, P. W</au><au>LAITINEN, L</au><au>LAURSEN, L</au><au>WENZEL, S</au><au>WOUTERS, E</au><au>DEAMER, L</au><au>NYSTROM, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early clinical investigation of Viozan (sibenadet HCl), a novel D2 dopamine receptor, β2-adrenoceptor agonist for the treatment of chronic obstructive pulmonary disease symptoms: Developing new therapies for chronic obstructive pulmonary disease: lessons learned from the novel D2/β2 agonist, ViozanTM</atitle><jtitle>Respiratory medicine</jtitle><date>2003</date><risdate>2003</risdate><volume>97</volume><spage>S9</spage><epage>S21</epage><pages>S9-S21</pages><issn>0954-6111</issn><eissn>1532-3064</eissn><cop>Oxford</cop><pub>Elsevier</pub></addata></record>
fulltext fulltext
identifier ISSN: 0954-6111
ispartof Respiratory medicine, 2003, Vol.97, p.S9-S21
issn 0954-6111
1532-3064
language eng
recordid cdi_pascalfrancis_primary_16111660
source Elsevier ScienceDirect Journals Complete; EZB-FREE-00999 freely available EZB journals
subjects Biological and medical sciences
Chronic obstructive pulmonary disease, asthma
Medical sciences
Pneumology
Respiratory system : syndromes and miscellaneous diseases
title Early clinical investigation of Viozan (sibenadet HCl), a novel D2 dopamine receptor, β2-adrenoceptor agonist for the treatment of chronic obstructive pulmonary disease symptoms: Developing new therapies for chronic obstructive pulmonary disease: lessons learned from the novel D2/β2 agonist, ViozanTM
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T10%3A07%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pascalfrancis&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20clinical%20investigation%20of%20Viozan%20(sibenadet%20HCl),%20a%20novel%20D2%20dopamine%20receptor,%20%CE%B22-adrenoceptor%20agonist%20for%20the%20treatment%20of%20chronic%20obstructive%20pulmonary%20disease%20symptoms:%20Developing%20new%20therapies%20for%20chronic%20obstructive%20pulmonary%20disease:%20lessons%20learned%20from%20the%20novel%20D2/%CE%B22%20agonist,%20ViozanTM&rft.jtitle=Respiratory%20medicine&rft.au=IND,%20P.%20W&rft.date=2003&rft.volume=97&rft.spage=S9&rft.epage=S21&rft.pages=S9-S21&rft.issn=0954-6111&rft.eissn=1532-3064&rft_id=info:doi/&rft_dat=%3Cpascalfrancis%3E16111660%3C/pascalfrancis%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true